PRT3645 is a highly potent, selective, and brain penetrant CDK4/6 inhibitor that has the potential to extend the reach of currently approved CDK4/6 inhibitors to address patients with brain metastasis and CNS cancers.
About
A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.